Skip to main content

Table 3 Analysis of the effect of infliximab on BMD using different linear regression models

From: A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

Models Cofactors Femoral neck BMD Lumbar BMD
   BMD variation P BMD variation P
1 Infliximab 0.027 0.001 0.030 0.001
2 Infliximab 0.027 0.001 0.031 0.001
  Male sex -0.009 0.40 0.008 0.47
  Age 0.002 0.56 0.005 0.09
3 Infliximab 0.020 0.03 0.033 0.001
  Male sex -0.014 0.22 0.006 0.64
  Age 0.001 0.86 0.005 0.15
  Patients on steroids -0.012 0.20 -0.001 0.92
4 Infliximab 0.023 0.01 0.034 0.001
  Male -0.014 0.22 0.006 0.61
  Age -0.001 0.90 -0.001 0.88
  Menopause 0.005 0.75 0.022 0.20
  Patients on steroids -0.010 0.29 -0.002 0.87
  DAS28 -0.008 0.04 -0.006 0.17
5 Infliximab 0.023 0.02 0.035 0.001
  Male -0.015 0.20 0.007 0.58
  Age -0.001 0.85 0.000 0.95
  Menopause 0.006 0.70 0.020 0.25
  Patients on steroids -0.009 0.37 -0.004 0.65
  DAS28 -0.008 0.05 -0.006 0.15
  Patients on biphosphonates -0.012 0.29 0.022 0.07
6 Infliximab 0.028 0.002 0.041 0.001
  Male -0.007 0.53 0.010 0.39
  Age -0.002 0.61 0.002 0.63
  Patients on steroids -0.008 0.35 -0.001 0.91
  DAS28 -0.007 0.06 -0.007 0.10
  Baseline BMD values -0.042 0.16 -0.080 0.01
  1. All 189 patients were included in several analysis of covariance models for bone mineral density (BMD) variations (final values minus initial values) to analyze the effect of cofactors (continuous variables and discrete variables) on that of infliximab. DAS, Disease Activity Score.